Brun, R., Don, R., Jacobs, R.T., Wang, M.Z. and Barrett, M.P. (2011) Development of novel drugs for human African trypanosomiasis. Future Microbiology, 6(6), pp. 677-691. (doi: 10.2217/fmb.11.44)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.2217/fmb.11.44
Abstract
Human African trypanosomiasis (HAT) or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei. Novel models for funding pharmaceutical development against HAT are beginning to yield results. The Drugs for Neglected Diseases initiative (DNDi) rediscovered a nitroimidazole, fexinidazole, which is currently in Phase I clinical trials. Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection. The Consortium for Parasitic Drug Development (CPDD) has identified a series of dicationic compounds that can cure a monkey model of stage two HAT. With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Barrett, Professor Michael |
Authors: | Brun, R., Don, R., Jacobs, R.T., Wang, M.Z., and Barrett, M.P. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | Future Microbiology |
ISSN: | 1746-0913 |
University Staff: Request a correction | Enlighten Editors: Update this record